SCHEDULE 13G/A: Schonfeld Strategic Advisors Discloses 4.93% Passive Stake in Terns Pharmaceuticals

Schonfeld Strategic Advisors LLC has filed an amended Schedule 13G, reporting a 4.93% passive beneficial ownership stake in Terns Pharmaceuticals, Inc. as of March 31, 2025.

Summary

• Schonfeld Strategic Advisors LLC, an investment adviser, reported beneficial ownership of 4,305,204 shares of Terns Pharmaceuticals, Inc. common stock.
• This stake represents 4.93% of Terns Pharmaceuticals' total outstanding common stock.
• The percentage is calculated based on 87,297,629 shares of common stock outstanding as of May 2, 2025, as disclosed by Terns Pharmaceuticals in its Quarterly Report on Form 10-Q filed on May 8, 2025.
• Schonfeld Strategic Advisors LLC holds sole voting power and sole dispositive power over all 4,305,204 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Terns Pharmaceuticals, Inc.

Sentiment

Score: 6

Explanation: The document itself is a neutral regulatory disclosure. However, the presence of a significant institutional investor like Schonfeld holding a passive stake can be interpreted as a mildly positive signal of confidence in the company, without implying any active engagement or specific future performance.

Positives

• The disclosure of a significant passive stake by an institutional investor like Schonfeld Strategic Advisors LLC may indicate a level of confidence in Terns Pharmaceuticals, Inc.'s long-term prospects.
• The passive nature of the investment (below 5% and explicitly not for control) suggests a non-activist, potentially stable, institutional holding.

Risks

• The document notes that the clients of Schonfeld's separately managed accounts (Schonfeld SMAs) are the record owners and have the right to receive dividends or proceeds from the sale of the securities, which is a standard ownership structure and not a specific risk.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Terns Pharmaceuticals, Inc.'s future performance or strategic outlook.

Management Comments

• Hung Luc, Chief Compliance Officer of Schonfeld Strategic Advisors LLC, certified that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing is a routine regulatory disclosure by an institutional investor in the biotechnology/pharmaceutical sector, indicating a significant, passive ownership stake in Terns Pharmaceuticals, Inc. Such disclosures provide transparency into the ownership structure of publicly traded companies and are common for investment advisers managing client assets.

Comparison to Industry Standards

• This Schedule 13G filing is standard for an investment adviser reporting a passive beneficial ownership stake below the 5% threshold that would typically trigger a more detailed Schedule 13D filing, which implies an intent to influence control. The 4.93% stake is consistent with a passive investment strategy.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and investor confidence.
• Management: Informs company management of a substantial passive shareholder, though no direct impact on operational or strategic decisions is implied by this type of filing.

Key Dates

Keywords

Terns Pharmaceuticals, Schonfeld Strategic Advisors, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Passive Investment, Biotechnology, Pharmaceuticals